Veriheal

OCTOBER 20, 2021

Always consult a physician before attempting psychedelic therapy. Data from a nationally representative sample of participants have been collected since 1975 to understand drug use trends among American young adults, and noteworthy findings are published each fall. Cannabis and magic mushrooms for the win!

Therapy 98

Therapy Microdosing Decriminalization Consumption 98

Cannabis Law Report

DECEMBER 8, 2021

Global Psychiatry Partnering 2014 to 2021 provides the full collection of Psychiatry disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Access to headline, upfront, milestone and royalty data. Specific therapy indication. Under what conditions can the deal be terminated?

Access 52

Access Data Pharmaceutical Research and Development 52

Cannabis Law Report

DECEMBER 2, 2021

The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021. IGC) engages in the development of cannabinoid-based therapies for healthcare applications. million individuals in the U.S.

Clinical Trials 52

Clinical Trials Data Patients THC 52

Cannabis Law Report

DECEMBER 14, 2021

(“IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. IGC), based in Maryland, engages in developing cannabinoid-based therapies for healthcare applications.

Clinical Trials 52

Clinical Trials Safety Data Patients 52

Cannabis Law Report

JUNE 23, 2021

Medicann is launching an observational study using RYAH Smart Dry Herb Inhalers in order to collect patient feedback on consumption of cannabis strains available on the Island, including strains supplied by Aurora Europe , a subsidiary of Canadian-headquartered Aurora Cannabis Inc., About RYAH Group, Inc. RYAH Group, Inc.

Programs 100

Programs Data Events Collective 100

Cannabis Law Report

DECEMBER 11, 2021

This reduction in prices will make the clinic the cheapest option for many patients looking to receive medical cannabis treatments for a wide variety of conditions and illnesses. Medical cannabis can be considered as a treatment for a number of conditions – including chronic pain, epilepsy, and insomnia – when first-line options have failed.

Access 52

Access Patients Chronic Pain Treatment 52

Cannabis Law Report

AUGUST 2, 2021

The diversified venture fund is focused on tackling the growing global mental health crisis by investing in innovative psychedelic-based and adjacent therapies that are poised to shape the future of psychiatry and fields beyond. Innovative psychedelic-based and adjacent therapies are poised to shape the future of psychiatry and fields beyond.

Research and Development 98

Research and Development Therapy Collective Treatment 98

SpeedWeed

SEPTEMBER 17, 2021

million to assess the efficacy of Multidisciplinary Association for Psychedelic Studies (MAPS) MDMA-assisted therapy to treat traumatic brain injury (TBI). Wesana is a serious, thoughtful and ethical company engaged in the development of psychedelic-assisted therapy. Lately, MAPS research zeroed in on MDMA-assisted therapy for PTSD.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

The Cannigma

NOVEMBER 11, 2021

These conditions are aimed to control any factors that might influence the results, also known as confounding variables. THC scores were also higher than placebo scales for psychotomimetic (psychotic-like) conditions such as mania, paranoia, and cognitive disorganization. CBD alters the subjective effects of THC.

CBD 139

CBD Research and Development THC Environment 139

Cannabis Law Report

JUNE 30, 2021

Yet, despite nearly two billion people with mental illness each year, these conditions are routinely misdiagnosed and inadequately treated. In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials.

Treatment 52

Treatment Clinical Trials Research and Development Data 52

Veriheal

OCTOBER 29, 2020

Of that, the American National Institute on Drug Abuse (NIDA) has invested just over $1 billion and has allocated far more money to researching cannabis misuse and the negative effects of consuming cannabis and its compounds as a form of therapy. The data for this graphic was provided by Jim Hudson at Hellth.com. . Canada, and the U.K)

Pharmaceutical 98

Pharmaceutical Therapy Cannabinoids Chronic Pain 98

Cannabis Law Report

NOVEMBER 3, 2021

This collectively brings the Company’s total clinic count to 15 globally. Zerenia™ Clinics UK follows the high-quality standards of personalised cannabinoid-based therapies and pursues precision-based medicine with the central goal to improve patient access to cannabinoid-based therapies.

Therapy 52

Therapy Access Patients Treatment 52

CannaMD

SEPTEMBER 10, 2020

Is it safe to continue cannabis-based therapies during pregnancy? This creates a somewhat confusing landscape for mothers who might benefit from cannabis-based therapies, but are also concerned for the safety of their child and the very real possibility of institutional intervention when marijuana use during pregnancy is documented.

Marijuana 59

Marijuana Therapy Data THC 59

Canna Law Blog

APRIL 13, 2019

These products have not been shown to be safe or effective, and deceptive marketing of unproven treatments may keep some patients from accessing appropriate, recognized therapies to treat serious and even fatal diseases.”. Specifically, the agency fears that.

CBD 90

CBD Safety Topical Food 90

Puff Puff Post

MARCH 10, 2020

INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. About INM-755: INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

AUGUST 10, 2021

Dried flower continues to dominate in the Veteran medical cannabis segment, accounting for over 60% of sales according to Canada House’s sales data. The purchase price also includes a performance-based cash earnout payment of $5 million, conditional upon MTL Cannabis achieving certain agreed upon milestones. Terms of the Transaction.

Seed-To-Sale 105

Seed-To-Sale Cultivation Patients Cannabis 105

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. Additionally, there are misleading practices of “p-hacking” where researchers can manipulate data through different statistical tests (thanks to modern computer programs) looking for statistically significant findings.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Veriheal

JULY 5, 2021

In spite of their fairly equal dominance in the legal cannabis space—collectively, these cannabinoids racked up $17.5 The self-reported data was logged between June 6, 2016, and July 8, 2019. Gastrointestinal conditions. Anti-nausea (antiemetic) therapies are often prescribed to nausea patients. billion in legal U.S.

THC 52

THC CBD Treatment Cannabinoids 52

Puff Puff Post

MARCH 10, 2020

INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. About INM-755: INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

MARCH 1, 2022

The parts of the Kratom tree, such as leaves, are utilized as herbal medicine for pain alleviation and other diseases.Today, Kratom is being utilized as a therapy for anxiety and despair. Dietary problems, chronic pain, and opiate addiction are among the conditions for which Kratom has been reported to be beneficial.

Strains 52

Strains Tincture Chronic Pain Medicine 52

The Herb Collective

JUNE 3, 2018

Recent clinical studies support its efficacy in burning fat cells, delaying the onset of chronic disease indicators, treating mental health conditions, and killing bacteria. In fact, it with the number of ailments and chronic conditions that it treats, it’s easy to understand why the product has a wonder drug appeal.

Oil 56

Oil CBD Blood Pressure Chronic Pain 56

The Joint Blog

OCTOBER 8, 2021

They offer effective treatment for anxiety & stress-related conditions without having any side effects on the body. Research by scientist and data collected: As of May 2018, there have only been a small amount of studies conducted in relation to CBD and it’s effect on stress.

Vaping 49

Vaping CBD Blood Pressure Chronic Pain 49

Cannabis Law Report

JULY 24, 2022

The market research company Data Bridge Market Research projects that the market capitalization of the psychedelic industry will grow 16.8 The collective term psychedelics or hallucinogens respectively (from Latin [h]al[l]ucinatio – thoughtless speech ) covers various substances that cause a perceptual and sensory disorder [2].

Research and Development 52

Research and Development Legalization Treatment Patients 52

Cannabis Law Report

JANUARY 4, 2022

Assay and Recently Developed, Unsupervised, At-Home Sample Collection Kit to Expand Addressable Market and Scope of COVID-19 Testing Services – STONY BROOK, N.Y.–(BUSINESS Assay”) as a Laboratory Developed Test (LDT), pending a final review of the assay’s validation data by NYSDOH. Assay (the “Linea 2.0 Assay (the “Linea 2.0

Conditions 52

Conditions Research and Development Therapy Supply Chain 52

Cannabis Law Report

JANUARY 21, 2022

Assay”) and Linea™ Unsupervised At-Home Sample Collection Kit (the “Linea Collection Kit”). The Assay previously received conditional approval from the New York State Department of Health in late December 2021. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) for its Linea™ 2.0 The Linea 2.0

Collective 52

Collective Therapy Research and Development Supply Chain 52

Cannabis Law Report

JULY 8, 2021

Instead, the punishments would include nothing at all, civil fines, drug education, and drug therapy. According to data from the National Survey on Drug Use and Health, 44 percent of men and 35 percent of women had smoked marijuana at some point in their lives. So yet, no state has legalised cannabis. percent or 16.7 percent or 15.2

Legalization 98

Legalization Advocacy Legislation Cannabis 98

Cannabis Law Report

JULY 28, 2021

The study was conducted by a respected contract research organization with deep expertise in preclinical oncology model development and drug testing and data corresponding to all studied cancer cell lines have now been reported to the Company.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

NOVEMBER 24, 2021

Medicinal cannabis has been legalised for use for a range of specified medical conditions in Australia since 2016. Media representations can offer insights into the nature of the discourse about new medical products and therapies and how ideas and understandings about social phenomena become constructed. Background. Conclusions.

Research and Development 52

Research and Development Medicine Access Media 52

Puff Puff Post

NOVEMBER 5, 2019

“We are very pleased with the preclinical data package, which further validates our scientific rationale and approach to treat EB, and look forward to starting the clinical phase of development and initiating subject screening and enrollment by year-end 2019.” For more information, visit www.inmedpharma.com.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Cannabis Law Report

OCTOBER 26, 2019

The TGA does not evaluate any data relating to the trial. Studies in which products already entered in the ARTG are used within the conditions of their marketing approval are not subject to CTN or CTX requirements but still need to be approved by an HREC. The institution at which the trial will be conducted gives the final approval.

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

The Cannigma

NOVEMBER 23, 2021

The app helps patients make sense of their journey by simplifying the information and supplying data-driven insights into their regimen and its effects. We delve into how data can further our understanding of different types of cannabis and why standardization is desperately needed in the industry.

Data 52

Data Patients Access Wellness and Beauty 52

Cannabis Law Report

NOVEMBER 7, 2019

Cannatrek will thoroughly control, analyse and optimise every step of its production to ensure the quality of the finished product using climatic and cultivation data combined with patient data, gathered in house. Huppert was one of the first entrepreneurs to enter the medicinal cannabis space in Australia.

Medicine 40

Medicine Patients Research and Development Clinical Trials 40

Puff Puff Post

NOVEMBER 5, 2019

“We are very pleased with the preclinical data package, which further validates our scientific rationale and approach to treat EB, and look forward to starting the clinical phase of development and initiating subject screening and enrollment by year-end 2019.” For more information, visit www.inmedpharma.com.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

Cannabis Law Report

OCTOBER 29, 2019

The PK data on cats shows there are differences in absorption between cats and dogs and that dosing may be different between these two species and that our chew form is likely to be more absorbable than oils in general. This data gives us confidence in the use of both the chew and the oils as effective means for delivering CBD to your pet.”.

Safety 45

Safety CBD Clinical Trials Oil 45

Cannabis Law Report

DECEMBER 7, 2021

Our audacious mission is to create the new standard of trust and transparency consumers deserve and healthcare providers demand on these widely accessible potential therapies. The large scale and intentional heterogeneity of our studies can transform these consumer health products into democratized precision solutions.”.

Clinical Trials 52

Clinical Trials CBD Data Sleep 52

Cannabis Law Report

JUNE 4, 2021

David John Nutt is an English neuropsychopharmacologist specialising in the research of drugs that affect the brain and conditions such as addiction, anxiety, and sleep. Graham contributes to Psilocybin Alpha as editor-at-large, providing data for patent trackers and writing about IP in the psychedelics space. David Nutt. Drug Science.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51

Cannabis Law Report

JULY 30, 2019

Most importantly, as participants in the state’s cannabis-collective experience, all patients ultimately choose a physician based on the ability of a mere 2,300 certified licensed doctors to see the sheer number of Florida patients, now past 300,000 active cardholders. . Consumer Reports- Can CBD Treat Opioid Addiction? .

Marijuana 45

Marijuana Patients Research and Development Programs 45